Adaptive Biotechnologies Corporation
ADPTHealthcareNASDAQDiagnostics & Research · Last scanned May 30, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Adaptive Biotechnologies Corporation focuses on Diagnostics & Research services and products. Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company carries a $2.42B market cap, placing it firmly in the mid-cap category. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.
Market Cap
$2.42B
Beta
2.16
P/E (TTM)
—
P/E (Fwd)
-58.92
EPS (TTM)
$-0.32
EPS (Fwd)
$-0.26
ROE
-24.0%
ROA
-5.7%
Cash
$218.3M
Total Debt
$208.2M
Free CF
$16.1M
52W Change
58.6%
Annual Financials
Cash vs Debt
With $218.3M in cash and $208.2M in debt, ADPT maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow comes in at $16.1M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at -24.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $154.3M (2021) to $277.0M (2025), reflecting a 79% increase over the period.
A beta of 2.16 means ADPT is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Adaptive Biotechnologies Corporation and its sector.